The dengue vaccines market is poised for robust expansion, with a projected total valuation set to reach US$ 474.8 million in 2023. Anticipated demand for dengue vaccines is on the rise, with a projected Compound Annual Growth Rate (CAGR) of 12.9% in sales volume (units).

Dengue vaccine development has reached a pivotal stage in its evolution, as numerous pharmaceutical industry leaders prepare to unveil the outcomes of extensive clinical trials conducted over the past decade or more. The forthcoming availability of various alternatives is expected to disrupt the prevailing dominance of the existing Denvaxia® vaccine

Request a Sample Copy of the Report Now
https://www.futuremarketinsights.com/reports/sample/rep-gb-1763

Geographic Overview

Latin America is expected to remain the second largest market for dengue vaccines, with a valuation of nearly US$ 290 million by the end of the forecast period. The report also predicts that more pharmaceutical companies will become involved in the expansion of the dengue vaccine market shortly.

According to the report, government institutes will continue to be the largest end-users of dengue vaccines. Dengue vaccine sales across government institutes will generate nearly US$650 million in revenue by the end of 2027. Furthermore, hospitals will maintain their dominance, with double-digit CAGRs throughout the forecast period. Sales of the sole vaccine, Dengvaxia, manufactured by Sanofi, are currently driving market growth. Furthermore, the factors influencing the market growth profiled in the report are discussed below.

Key Highlights of Dengue Vaccines Market Report

  1. Other than the burdening occurrence of dengue in some countries, the economic turmoil in Latin America is estimated to influence the growth of the global market at the macroeconomic level.
  2. Live attenuated vaccines are also produced and developed economically, thereby consoling the vaccine market and patients.
  3. Low availability of optimum diagnostic systems and lack of skilled professionals have led to cases, where dengue fever is being treated as undistinguished febrile disease.
  4. The global market of dengue vaccines is likely to secure an opportunistic revolution when companies are likely to able to successfully develop effective vaccines for all age groups.

Overall, the global dengue vaccines market, which is currently valued at nearly US$ 250 million, will increase rapidly to reach over US$ 1,250 million in terms of revenues, by the end of 2027.

Revealing the hidden assumptions of the study. Talk to Analyst
https://www.futuremarketinsights.com/ask-question/rep-gb-1763

According to FMI’s report, the following dengue vaccine manufacturers operate within the global market landscape:

  • Sanofi Pasteur Limited
  • Takeda Pharmaceutical Company Limited
  • Merck & Co. Inc.
  • GlaxoSmithKline Plc.
  • GeneOne Life Science Inc.
  • Medigen Vaccine Biologics Corporation
  • Panacea Biotec Limited
  • Sun Pharmaceutical Industries Ltd
  • Serum Institute of India Pvt. Ltd.
  • Biological E Ltd.

Key Segments Covered

Product

  • CYD-TDV (Dengvaxia)

End-User

  • Hospitals
  • Government Institutes
  • Non-governmental Organizations (NGOs)

Region

  • North America (US and Canada)
  • Latin America (Brazil, Mexico, Venezuela, and the Rest of LATAM)
  • Western Europe (Germany, UK, France, Spain, Italy and Rest of Western Europe)
  • Eastern Europe (Russia, Poland and Rest of Eastern Europe)
  • APEJ (The Philippines, Indonesia, Malaysia, Thailand, Vietnam, India and Rest of APEJ)
  • Japan
  • Middle East & Africa (GCC, Northern Africa, South Africa and Rest of MEA)

Tap into Comprehensive Segmented Information – Purchase Now
https://www.futuremarketinsights.com/checkout/1763

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

Leave a comment

Your email address will not be published. Required fields are marked *